<?xml version="1.0" encoding="UTF-8"?>
<p id="p0620">Emetine 
 <bold>(43)</bold> is an approved anti-protozoal drug used against amebae with reported inhibitory activity for enterovirus infections,
 <xref rid="b1500" ref-type="bibr">
  <sup>300</sup>
 </xref> Zika virus and Ebola by interfering with the process of viral replication and entry in host cells.
 <xref rid="b1505" ref-type="bibr">
  <sup>301</sup>
 </xref> Emetine is an isoquinoline alkaloid that presents 4 methoxy groups in its structure (
 <xref rid="f0040" ref-type="fig">Fig. 8</xref> ). Studies also confirm emetine has 
 <italic>in-vitro</italic> activity against coronaviruses, including SARS-CoV and MERS-CoV.
 <xref rid="b0490" ref-type="bibr">98</xref>, 
 <xref rid="b1510" ref-type="bibr">302</xref> Regarding SARS-CoV-2, 
 <italic>in-vitro</italic> assays with emetine showed effective viral inhibition at concentrations of 0.5 µM,
 <xref rid="b0545" ref-type="bibr">
  <sup>109</sup>
 </xref> which is much superior to the concentration of 0.075 µg/mL used for therapeutic purposes. In order to reduce the effective concentrations of emetine and fit it into acceptable therapeutic parameters, Choy et al.
 <xref rid="b0545" ref-type="bibr">
  <sup>109</sup>
 </xref> tested combinations of RDV and emetine and achieved inhibition of 64.9% at concentrations of 6.25 µM for RDV and 0.195 µM for emetine. Nonetheless, researchers highlight the need for further 
 <italic>in-vitro</italic> assays to clarify the activity of these drugs and the mechanism involved in the antiviral action of emetine both in isolation and combined to other drugs.
</p>
